Reeling from PD-1 slapdown, Incyte stirs concerns with side effects of oral PD-L1 — although drug is also 'clearly active'
The rejection of its PD-1 inhibitor, retifanlimab, was never going to be the end of Incyte’s checkpoint story. Not only was the biotech holding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
